

Mark Mirochnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4119478/publications.pdf>

Version: 2024-02-01

52
papers

1,412
citations

331538

21
h-index

345118

36
g-index

55
all docs

55
docs citations

55
times ranked

1139
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetics of Antiretrovirals in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2004, 43, 1071-1087.	1.6	137
2	Antiretroviral Concentrations in Breast-Feeding Infants of Mothers Receiving Highly Active Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1170-1176.	1.4	103
3	Atazanavir Pharmacokinetics With and Without Tenofovir During Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, 412-419.	0.9	91
4	Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. <i>Aids</i> , 2018, 32, 729-737.	1.0	72
5	Concentrations of protease inhibitors in cord blood after in utero exposure. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 835-838.	1.1	69
6	Lopinavir Exposure With an Increased Dose During Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 485-491.	0.9	62
7	Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 33-41.	0.9	60
8	Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 153-156.	0.9	56
9	Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV. <i>Aids</i> , 2018, 32, 2507-2516.	1.0	55
10	Importance of Prospective Studies in Pregnant and Breastfeeding Women Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2019, 69, 1254-1258.	2.9	47
11	Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. <i>Clinical Infectious Diseases</i> , 2016, 62, 761-769.	2.9	43
12	Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. <i>PLoS ONE</i> , 2018, 13, e0189851.	1.1	42
13	Antiretroviral Pharmacology in Pregnant Women and Their Newborns. <i>Annals of the New York Academy of Sciences</i> , 2000, 918, 287-297.	1.8	40
14	Nelfinavir and Lamivudine Pharmacokinetics During the First Two Weeks of Life. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 769-772.	1.1	36
15	Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	30
16	Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 36-48.	2.3	29
17	Tenofovir alafenamide use in pregnant and lactating women living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 333-342.	1.5	28
18	Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHDP1081): an open-label, randomised, controlled, phase 4 trial. <i>Lancet HIV</i> , 2020, 7, e322-e331.	2.1	27

#	ARTICLE	IF	CITATIONS
19	Congenital Cytomegalovirus and HIV Perinatal Transmission. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1016-1021.	1.1	26
20	Antiretroviral Pharmacology: Special Issues Regarding Pregnant Women and Neonates. <i>Clinics in Perinatology</i> , 2010, 37, 907-927.	0.8	24
21	Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. <i>Lancet HIV</i> , 2019, 6, e552-e558.	2.1	24
22	Darunavir Pharmacokinetics With an Increased Dose During Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 83, 373-380.	0.9	19
23	The last and first frontier “ emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. <i>Journal of the International AIDS Society</i> , 2015, 18, 20271.	1.2	19
24	Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women. <i>Clinical Infectious Diseases</i> , 2015, 61, 1582-1589.	2.9	16
25	Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1185-1194.	1.6	16
26	Efavirenz pharmacokinetics during pregnancy and infant washout. <i>Antiviral Therapy</i> , 2018, 24, 95-103.	0.6	15
27	Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 86, 607-615.	0.9	15
28	Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV. <i>Aids</i> , 2021, 35, 407-417.	1.0	15
29	Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 83-93.	1.3	14
30	Nevirapine concentrations in newborns receiving an extended prophylactic regimen. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 334-7.	0.9	14
31	Ritonavir and cobicistat as pharmacokinetic enhancers in pregnant women. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 523-525.	1.5	13
32	Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2020, 84, 70-77.	0.9	13
33	Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. <i>Lancet HIV</i> , 2021, 8, e149-e157.	2.1	12
34	Can traditional birth attendants be trained to accurately identify septic infants, initiate antibiotics, and refer in a rural African setting?. <i>Global Health, Science and Practice</i> , 2014, 2, 318-327.	0.6	11
35	Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 386-393.	1.0	11
36	Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	11

#	ARTICLE	IF	CITATIONS
37	Population Pharmacokinetics of Tenofovir in Pregnant and Postpartum Women Using Tenofovir Disoproxil Fumarate. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	11
38	Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 189-94.	0.9	9
39	Population pharmacokinetics of dapson in children with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 24-32.	2.3	8
40	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1348-1356.	1.3	8
41	Pharmacokinetic Enhancement of HIV Antiretroviral Therapy During Pregnancy. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1537-1550.	1.0	8
42	One dose does not fit all: revising the WHO paediatric dosing tool to include the non-linear effect of body size and maturation. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 9-10.	2.7	8
43	Maternalâ€œNeonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 643-653.	1.3	7
44	Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 392-398.	0.9	6
45	Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development. <i>Frontiers in Pediatrics</i> , 2021, 9, 721059.	0.9	6
46	Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. <i>Lancet HIV</i> , the, 2022, 9, e24-e31.	2.1	6
47	Optimizing Dolutegravir Initiation in Neonates using Population Pharmacokinetic Modeling and Simulation. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 108-114.	0.9	4
48	Lopinavir and tenofovir interaction observed in nonâ€œpregnant adults altered during pregnancy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 1459-1464.	0.7	3
49	Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. <i>Clinical Infectious Diseases</i> , 2022, 75, 1037-1045.	2.9	3
50	Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens. <i>Contraception</i> , 2022, 105, 67-74.	0.8	2
51	Vaginal Viral Shedding with Undetectable Plasma HIV Viral Load in Pregnant Women Receiving Two Different Antiretroviral Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 361-365.	0.9	1
52	Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 626-634.	0.9	0